Regenxbio Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy RGNX?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to significant investor losses once the truth was revealed.
- Market Reaction: Following the revelation of Regenxbio's misleading statements, investor losses increased significantly, indicating a major failure in the company's disclosure practices that could undermine future investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected shareholders to join the lawsuit for compensation, demonstrating the firm's commitment to protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.490
Low
19.00
Averages
29.71
High
45.00
Current: 9.490
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors seeking justice.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
Regenxbio Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study further confirms the company's concealment of product safety, potentially eroding investor confidence and affecting future financing capabilities for the company.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to participate in the lawsuit to seek compensation, highlighting the legal avenue available for investors to recover their losses.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed, indicating a pattern of false and misleading public statements throughout the class period.
- Market Reaction: Following the revelation of concealed negative information, investor losses surged, highlighting the company's major missteps in disclosure practices, which could lead to a trust crisis and impact future financing capabilities.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to join the lawsuit for potential recovery, underscoring the importance of legal avenues in protecting shareholder rights.
See More
REGENXBIO Class Action Lawsuit Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development of RGX-111 gene therapy, claiming positive biomarker and safety data while concealing material adverse facts about the therapy's efficacy and safety, resulting in investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Selection Advice: The law firm advises investors to choose qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure optimal legal support and representation in the class action.
See More
Faruqi & Faruqi Encourages REGENXBIO Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased or acquired securities between February 9, 2022, and January 27, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to investor advocacy.
- Class Action Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Impact Assessment: This legal action could negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to make informed investment decisions.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors seeking justice.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
Regenxbio Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study further confirms the company's concealment of product safety, potentially eroding investor confidence and affecting future financing capabilities for the company.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to participate in the lawsuit to seek compensation, highlighting the legal avenue available for investors to recover their losses.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed, indicating a pattern of false and misleading public statements throughout the class period.
- Market Reaction: Following the revelation of concealed negative information, investor losses surged, highlighting the company's major missteps in disclosure practices, which could lead to a trust crisis and impact future financing capabilities.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to join the lawsuit for potential recovery, underscoring the importance of legal avenues in protecting shareholder rights.
See More
REGENXBIO Class Action Lawsuit Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development of RGX-111 gene therapy, claiming positive biomarker and safety data while concealing material adverse facts about the therapy's efficacy and safety, resulting in investor losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Selection Advice: The law firm advises investors to choose qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure optimal legal support and representation in the class action.
See More
Faruqi & Faruqi Encourages REGENXBIO Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, specifically targeting investors who purchased or acquired securities between February 9, 2022, and January 27, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to investor advocacy.
- Class Action Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Impact Assessment: This legal action could negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to make informed investment decisions.
See More
